Day AT, Sher DJ, Lee RC, Truelson JM, Myers LL, Sumer BD, Stankova L, Tillman BN, Hughes RS, Khan SA, Gordin EA (2020) Head and neck oncology during the COVID-19 pandemic: reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. Oral Oncol 105:104684. https://doi.org/10.1016/j.oraloncology.2020.104684

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM-H, Lin J-C, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, Cohen E (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22:450–462. https://doi.org/10.1016/s1470-2045(20)30737-3

Article  CAS  PubMed  Google Scholar 

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Prim 6:92. https://doi.org/10.1038/s41572-020-00224-3

Article  PubMed  Google Scholar 

Xia Y, Liu S, Li C, Ai Z, Shen W, Ren W, Yang X (2020) Discovery of a novel ferroptosis inducer-talaroconvolutin A—killing colorectal cancer cells in vitro and in vivo. Cell Death Dis 11:988. https://doi.org/10.1038/s41419-020-03194-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA, Lei P (2021) Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther 6:49. https://doi.org/10.1038/s41392-020-00428-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Trumbach D, Mao G, Qu F, Bayir H, Fullekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13:91–98. https://doi.org/10.1038/nchembio.2239

Article  CAS  PubMed  Google Scholar 

Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, Liu D, Zhang F, Ning S, Yao J, Tian X (2019) Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ 26:2284–2299. https://doi.org/10.1038/s41418-019-0299-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch A, Eggenhofer E, Basavarajappa D, Radmark O, Kobayashi S, Seibt T, Beck H, Neff F, Esposito I, Wanke R, Forster H, Yefremova O, Heinrichmeyer M, Bornkamm GW, Geissler EK, Thomas SB, Stockwell BR, O’Donnell VB, Kagan VE, Schick JA, Conrad M (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 16:1180–1191. https://doi.org/10.1038/ncb3064

Article  CAS  PubMed  Google Scholar 

Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy, protein. Cell 12:599–620. https://doi.org/10.1007/s13238-020-00789-5

Article  CAS  Google Scholar 

Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF, Zhang J, Wang H, Chen X, Yan C (2020) ATF3 promotes erastin-induced ferroptosis by suppressing system Xc–. Cell Death Differ 27:662–675. https://doi.org/10.1038/s41418-019-0380-z

Article  CAS  PubMed  Google Scholar 

Lang X, Green MD, Wang W, Yu J, Choi JE, Jiang L, Liao P, Zhou J, Zhang Q, Dow A, Saripalli AL, Kryczek I, Wei S, Szeliga W, Vatan L, Stone EM, Georgiou G, Cieslik M, Wahl DR, Morgan MA, Chinnaiyan AM, Lawrence TS, Zou W (2019) Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov 9:1673–1685. https://doi.org/10.1158/2159-8290.CD-19-0338

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Liu Q, Jiang Y, Cai Z, Liu H, Zuo H (2023) Engineered small extracellular vesicles loaded with miR-654–5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. Cell Death Dis. https://doi.org/10.1038/s41420-023-01660-2

Article  PubMed  PubMed Central  Google Scholar 

Friedmann Angeli JP, Krysko DV, Conrad M (2019) Ferroptosis at the crossroads of cancer—acquired drug resistance and immune evasion. Nat Rev Cancer 19:405–414. https://doi.org/10.1038/s41568-019-0149-1

Article  CAS  PubMed  Google Scholar 

Gheghiani L, Wang L, Zhang Y, Moore XTR, Zhang J, Smith SC, Tian Y, Wang L, Turner K, Jackson-Cook CK, Mukhopadhyay ND, Fu Z (2021) PLK1 induces chromosomal instability and overrides cell-cycle checkpoints to drive tumorigenesis. Can Res 81:1293–1307. https://doi.org/10.1158/0008-5472.Can-20-1377

Article  CAS  Google Scholar 

De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K, Di Cristofano A (2018) PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett 439:56–65. https://doi.org/10.1016/j.canlet.2018.09.024

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao W, Zhang Y, Luo H, Niu M, Zheng X, Hu W, Cui J, Xue X, Bo Y, Dai F, Lu Y, Yang D, Guo Y, Guo H, Li H, Zhang Y, Yang T, Li L, Zhang L, Hou R, Wen S, An C, Ma T, Jin L, Xu W, Wu Y (2020) Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma via impairing PLK1–AKT axis-mediated glycolysis. Cell Death Dis. https://doi.org/10.1038/s41419-020-03104-6

Article  PubMed  PubMed Central  Google Scholar 

Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, Dahmani A, Painsec P, Nemati F, Vacher S, Chemlali W, Masliah-Planchon J, Château-Joubert S, Rega C, Leal MF, Simigdala N, Pancholi S, Ribas R, Nicolas A, Meseure D, Vincent-Salomon A, Reyes C, Rapinat A, Gentien D, Larcher T, Bohec M, Baulande S, Bernard V, Decaudin D, Coussy F, Le Romancer M, Dutertre G, Tariq Z, Cottu P, Driouch K, Bièche I, Martin L-A, Marangoni E (2020) PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat Commun. https://doi.org/10.1038/s41467-020-17697-1

Article  PubMed  PubMed Central  Google Scholar 

Yu Z, Deng P, Chen Y, Liu S, Chen J, Yang Z, Chen J, Fan X, Wang P, Cai Z, Wang Y, Hu P, Lin D, Xiao R, Zou Y, Huang Y, Yu Q, Lan P, Tan J, Wu X (2021) Inhibition of the PLK1-coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer. Adv Sci. https://doi.org/10.1002/advs.202100759

Article  Google Scholar 

Liu Z, Sun Q, Wang X (2017) PLK1, a potential target for cancer therapy. Transl Oncol 10:22–32. https://doi.org/10.1016/j.tranon.2016.10.003

Article  PubMed  Google Scholar 

Zhang L, Wang Z, Liu R, Li Z, Lin J, Wojciechowicz ML, Huang J, Lee K, A. Ma’ayan, J.C. He. (2021) Connectivity mapping identifies BI-2536 as a potential drug to treat diabetic kidney disease. Diabetes. https://doi.org/10.2337/db20-0580

Article  PubMed  PubMed Central  Google Scholar 

Lin RC, Chao YY, Lien WC, Chang HC, Tsai SW, Wang CY (2023) Polo-like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM-ERK cascade in adrenocortical carcinoma. Oncol Rep. https://doi.org/10.3892/or.2023.8604

Article  PubMed  PubMed Central  Google Scholar 

Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R, Danna Y, Li J, Fan J, Chen J, Zhang W, Zhan Q (2019) A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine 41:244–255. https://doi.org/10.1016/j.ebiom.2019.02.012

Article  PubMed  PubMed Central  Google Scholar 

Lian G, Li L, Shi Y, Jing C, Liu J, Guo X, Zhang Q, Dai T, Ye F, Wang Y, Chen M (2018) BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. Int J Oncol. https://doi.org/10.3892/ijo.2018.4255

Article  PubMed  PubMed Central  Google Scholar 

Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317–331. https://doi.org/10.1016/j.cell.2013.12.010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang WS, Stockwell BR (2016) Ferroptosis: death by lipid peroxidation. Trend Cell Biol 26:165–176. https://doi.org/10.1016/j.tcb.2015.10.014

Article  CAS  Google Scholar 

Chen G-Q, Benthani FA, Wu J, Liang D, Bian Z-X, Jiang X (2019) Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ 27:242–254. https://doi.org/10.1038/s41418-019-0352-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T (2021) Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res 81:1583–1594. https://doi.org/10.1158/0008-5472.CAN-20-3477

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang J, Mo J, Dai J, Ye C, Cen W, Zheng X, Jiang L, Ye L (2021) Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. https://doi.org/10.1038/s41419-021-04367-3

Article  PubMed  PubMed Central  Google Scholar 

Liang C, Zhang X, Yang M, Dong X (2019) Recent progress in ferroptosis inducers for cancer therapy. Adv Mater 31:e1904197. https://doi.org/10.1002/adma.201904197

Article  CAS  PubMed